Wanbury Ltd Reports 154% YoY Growth in PAT for Q4FY25, Launches Two New Products

Wanbury Ltd, a pharmaceutical company, has announced its financial results for the quarter and year ended 31st March, 2025. The company reported a YoY growth of 23% in revenue from operations, driven by higher sales volumes in key API products such as Metformin & Sertraline. EBITDA surged by 65% and PAT increased by 154%. The company also launched two new products: Wanbury C-RED, an iron supplement, and Ketamine Hydrochloride, a controlled substance used in surgeries. The Tanuku manufacturing facility successfully completed an ANVISA (Brazil FDA) inspection with zero observations. Wanbury has initiated a digital transformation journey with plans to implement SAP S/4 HANA Private Cloud. The company has also strengthened its leadership team with new appointments.